Robbins LLP Urges REPL Investors to Act Before October 5 Deadline for Class Action Claims

REPL Stockholders Should Act Promptly with Robbins LLP

In a critical update for investors of Replimune Group, Inc. (NASDAQ: REPL), renowned law firm Robbins LLP has emphasized the urgency for shareholders who encountered significant losses during a specific period to engage with them. The firm is representing a class action that pertains to all entities and individuals who acquired REPL securities from October 20, 2025, to April 10, 2026. This period is crucial as it includes events that allegedly misled investors about the efficacy of Replimune’s leading product candidate, RP1 (vusolimogene oderparepvec).

What Caused the Class Action?

The class action stems from Replimune's announcements regarding their biological license application for RP1 in combination with nivolumab as a treatment for advanced melanoma. On October 20, 2025, the company claimed that the U.S. Food and Drug Administration (FDA) accepted its resubmission of the application. They asserted that they had included additional data meant to support their case.

However, the lawsuit alleges that there were crucial omissions from this statement. Key points raised in the complaint highlight that:
1. Concerns that the FDA had previously communicated about the study design were not adequately addressed by Replimune.
2. Early analysis data came from a mere 10% of the planned patient pool, raising questions about the study's robustness.
3. These inadequacies likely resulted in the FDA disapproving the application.
4. Investors were misled regarding the company's business prospects based on these false representations.

The Fallout from FDA’s Decision

The situation escalated dramatically when, on April 10, 2026, the FDA issued a Complete Response Letter (CRL) rejecting the application for RP1. The letter cited multiple deficiencies, leading to a staggering 19.46% drop in the company’s share price shortly after the announcement. Following further clarifications from the company regarding the FDA’s preference for a randomized controlled trial, shares plummeted an additional 64.29%, prompting shareholders to reconsider their initial investments in light of these developments.

This alarming decline signifies an important turning point for investors who may seek recovery for their losses. Those who acquired REPL shares during the mentioned timeframe are encouraged to reach out to Robbins LLP, as they are yet to discover their potential legal rights under current circumstances.

The Role of the Lead Plaintiff

In this type of class action, a lead plaintiff acts on behalf of all class members and helps steer the case through the legal system. Interested investors must file their papers requesting this status by October 5, 2026. Most importantly, participation does not require someone to become the lead plaintiff, as they may still recover their losses through the class action.

No Upfront Costs to Participate

Robbins LLP assures investors that taking part in this litigation involves no upfront cost, operating instead on a contingency fee basis. This means that the firm will collect fees only if the case is resolved favorably for the investors.

Why Choose Robbins LLP?

Robbins LLP has established itself as a leader in shareholder rights litigation, successfully recovering over $2 billion for shareholders in the past. Their commitment to holding corporations accountable and ensuring transparency for shareholders underpins their approach. Brian J. Robbins, the founding partner, emphasizes the importance of responsible governance in his firm's philosophy.

Stay Informed and Act Now

Investors can stay updated on the Replimune Class Action by submitting inquiries, contacting Robbins LLP via email, or calling their dedicated helpline. Current and potential investors should remain vigilant, as the financial implications of this case may continue to unfold, and acting promptly may facilitate recovery efforts.

To further explore potential claims or to seek necessary legal advice, investors are encouraged to engage with Robbins LLP without delay, particularly before the looming deadline.